PharmaShots | Incisive News in 3 Shots

Subscribe Now

Sobi

Sobi’s Altuvoct Receives the EC’s Marketing Authorization to Treat Haemophilia A

Sobi’s Altuvoct Receives the EC’s Marketing Authorization to Treat Haemophilia A

June 19, 2024

Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A

Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A

May 19, 2023

Sobi to Acquire CTI BioPharma for ~$1.7B

Sobi to Acquire CTI BioPharma for ~$1.7B

May 11, 2023

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

April 3, 2023

Sobi and ADC Therapeutics Zynlonta (loncastuximab tesirine) Receives EC’s Conditional Marketing Authorisation for Diffuse Large B-Cell Lymphoma

Sobi and ADC Therapeutics Zynlonta (loncastuximab tesirine) Receives EC’s Conditional Marketing Authorisation for Diffuse Large B-...

December 21, 2022

Sobi and Sanofi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) study for the Treatment of Haemophilia A

Sobi and Sanofi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) study for the Treatment of Haemophilia A

March 9, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us